4d • General discussion
📚 RESEARCH MONDAY
PERIOD POOPS ARE REAL — BUT ARE PROSTAGLANDINS THE WHOLE STORY?
Ever notice your period starts and suddenly your stomach decides it wants to participate too?
Cramping. Bloating. Nausea. Looser stools. More bathroom trips.
Most explanations stop at:
“It’s prostaglandins.”
That explanation isn’t wrong.
But after looking deeper at the research, I think it’s too simple.
🟢 WHAT WE KNOW WITH THE MOST CONFIDENCE
A 2025 systematic review examined biomarkers found in menstrual fluid from women with dysmenorrhea—painful periods.
15 studies. 223 participants.
Eight studies consistently found higher prostaglandin levels in women experiencing dysmenorrhea, and seven studies found that NSAIDs reduced prostaglandin concentrations.
So the pathway:
prostaglandins → stronger uterine contractions → menstrual pain
has meaningful biological support.
Evidence tier: 🟢 ESTABLISHED / MODERATE-HIGH CONFIDENCE
The evidence isn’t perfect—the underlying studies were generally small—but the same biological mechanism has been investigated for decades.
BUT WHAT ABOUT YOUR BOWELS?
This is where the evidence gets more interesting.
A study of 156 healthy premenopausal women found that 73% experienced at least one gastrointestinal symptom before or during menstruation.
During menstruation, 28% reported diarrhea.
Another prospective study found stools were significantly loosest during menstruation compared with other cycle phases.
So menstrual-related GI changes absolutely occur.
But…
A separate study followed 53 women for three menstrual cycles.
Stomach pain and nausea were associated with uterine cramping.
But:
diarrhea, constipation and stool characteristics were NOT significantly associated with how severe the cramps were.
That’s important.
Because it tells us that the relationship may be more complicated than:
more prostaglandins = worse cramps = more diarrhea.
🧠 IN PLAIN ENGLISH
Think of prostaglandins like your body’s group text for inflammation and contraction.
When menstruation begins, these chemical signals help the uterus contract.
When their activity becomes excessive, they can contribute to painful periods.
And because the reproductive and gastrointestinal systems don’t exist in completely isolated bubbles, those same menstrual changes may contribute to GI symptoms.
But the human evidence doesn’t let us confidently say:
“Prostaglandins alone explain every woman’s period poops.”
Better answer:
They’re probably part of the story.
Not necessarily the whole story.
🔎 CURIOSITY CORNER
This is the kind of research I want us paying attention to.
The 2025 systematic review identified other inflammatory molecules besides prostaglandins.
Two studies pointed toward:
12-HETE
and
platelet-activating factor — PAF
as possible contributors to menstrual pain.
Researchers raised an interesting possibility:
Some women whose pain doesn’t respond well to NSAIDs may have inflammatory pathways that aren’t primarily driven by the prostaglandin pathway NSAIDs target.
Does that prove this is happening?
❌ No.
Does it mean women should start taking completely different drugs?
❌ No.
Why talk about it then?
Because it raises a question worth studying:
What if menstrual pain isn’t driven by exactly the same inflammatory pathway in every woman?
That could eventually help explain why one woman gets excellent relief from an NSAID while another barely responds.
Evidence tier: 🔴 EARLY / HYPOTHESIS-GENERATING
Interesting?
Absolutely.
Ready to change clinical recommendations?
Not even close.
👩 WHAT THIS MEANS FOR EVERYDAY WOMEN
If your bowel habits consistently change when menstruation begins, you’re not imagining something unusual.
But don’t jump immediately to:
“My hormones are out of balance.”
Instead start asking:
When does it happen?
Does it happen every cycle?
Does it occur with cramps—or independently?
Does it stop once menstruation ends?
How severe is it?
Your pattern is information.
🐐 GOATGETheR TAKE
I don’t want this community learning science like this:
“Period poop = prostaglandins. Done.”
I want us thinking like this:
“GI changes during menstruation are documented. Prostaglandins have strong evidence in menstrual pain and probably contribute to some systemic symptoms. But the bowel connection isn’t completely explained, and researchers are investigating additional inflammatory pathways.”
That’s a messier answer.
It’s also a much more accurate one.
Science isn’t just knowing what we know.
It’s recognizing exactly where our certainty ends.
✅ YOUR EXPERIMENT
During your next cycle, track:
Cycle day
Cramps 0–10
Stool changes
Bloating 0–10
Nausea 0–10
Then ask:
Do my bowel changes actually track with my cramping?
We’re not diagnosing anything.
We’re collecting your pattern.
🚫 MYTH CHECK
“Period diarrhea means my hormones are messed up.”
❌ Not necessarily.
GI symptoms occur commonly around menstruation.
“Scientists know it’s definitely just prostaglandins.”
❌ Too confident.
Prostaglandins clearly matter, but research suggests menstrual pain and GI symptoms involve a more complicated biological system.
⏱️ ONE-MINUTE SUMMARY
What we know:
GI symptoms commonly occur around menstruation.
Strongest mechanism:
Prostaglandins play an established role in uterine contractions and dysmenorrhea.
What we’re less sure about:
How much prostaglandins directly explain individual bowel changes.
Emerging research:
Other inflammatory pathways involving molecules like 12-HETE and PAF may also matter.
What we’re watching:
Whether different women experience menstrual pain through different dominant biological pathways.
Confidence
Prostaglandins + menstrual pain: 🟢 8.5/10
Menstruation + GI changes: 🟢 8/10
Prostaglandins alone explaining period diarrhea: 🟡 6/10
12-HETE/PAF as future treatment targets: 🔴 2–3/10
🧬 PEPTIDE SPOTLIGHT
GLP-1 WEIGHT LOSS: ARE YOU LOSING MUSCLE… OR ARE WE ASKING THE WRONG QUESTION?
We’ve all heard both extremes:
“GLP-1 drugs eat your muscle.”
and
“Don’t worry about muscle loss—the weight you’re losing is basically all fat.”
The evidence says:
Neither statement is good enough.
🟢 WHAT THE STRONGER EVIDENCE SAYS
A 2026 systematic review and meta-analysis pooled 20 randomized controlled trials involving 15,782 participants receiving incretin-based medications or lifestyle interventions.
Lean mass represented approximately:
Semaglutide → 35% of total weight lost
Tirzepatide → 25%
Liraglutide → 27%
Lifestyle-only weight loss produced a similar proportion.
But when lifestyle treatment included resistance training, lean mass represented only about 17.5% of total weight lost.
First lesson:
When someone loses substantial weight, some lean tissue loss is common.
That’s not unique to GLP-1 medications.
Second lesson:
Resistance training may matter enormously.
WAIT — “LEAN MASS” DOESN’T MEAN “MUSCLE”
This distinction is important.
DXA body-composition scans generally divide you into:
Fat mass
and
lean mass.
But lean mass includes more than skeletal muscle.
It also includes things like body water, organs and other non-fat tissue.
So if a study says:
“Participants lost 3 kg of lean mass,”
you cannot automatically translate that into:
“They lost 3 kg of muscle.”
That’s one reason this topic is more complicated than the headlines suggest.
🔎 NOW HERE’S THE INTERESTING PART
The prospective SEMALEAN study followed people with obesity receiving semaglutide 2.4 mg.
115 people entered. 106 completed the study. About 69% were women.
At seven months, participants had lost approximately 3 kg of lean mass.
Then something interesting happened.
Lean mass stabilized between months seven and twelve.
And at 12 months:
hand-grip strength increased by approximately 4.5 kg.
So now we have a fascinating question:
How can someone’s measured lean mass decrease while their physical strength improves?
That’s exactly the kind of finding I want GOATGETheR digging into.
🟡 EMERGING EVIDENCE: MUSCLE QUANTITY VS MUSCLE QUALITY
Researchers are increasingly separating two concepts:
Muscle quantity
How much tissue appears to be there.
versus
Muscle quality
How well that tissue actually functions.
A 2025 review examining incretin therapies and skeletal muscle noted that preclinical and early clinical research suggests potential improvements in things like:
mitochondrial function
intramuscular fat
inflammation
and
muscle metabolic efficiency.
But this is where we need discipline.
Much of the mechanistic evidence is still:
- Animal research
- Cellular research
- Early clinical work
- Indirect physiological evidence
So we cannot say:
“GLP-1s improve your muscles.”
That’s stronger than the evidence.
Evidence tier: 🟡/🔴 EMERGING
The hypothesis is interesting.
The clinical answer isn’t settled.
🔎 CURIOSITY CORNER
Here’s the question I think researchers should keep chasing:
During major weight loss, should we care more about the number of kilograms labeled “lean mass” — or about actual strength, mobility and muscle function?
Because those aren’t always the same thing.
The randomized SURMOUNT-1 DXA substudy adds another piece.
Among 160 participants—73% women— treated with tirzepatide, approximately:
75% of the weight lost was fat mass
and
25% was lean mass.
So lean mass loss is real.
But the larger scientific question is:
Does that amount of lean tissue loss translate into worse physical function?
Right now, we don’t have enough high-quality long-term evidence to answer that for every population.
And the answer may be very different for:
- A healthy 30-year-old woman with substantial muscle reserves
- A 70-year-old woman already approaching sarcopenia
- A competitive athlete
- Someone who never resistance trains
- Someone consuming inadequate protein
Those populations should not automatically be treated like they’re identical.
🐐 GOATGETheR TAKE
I don’t think the useful conversation is:
“GLP-1s cause muscle loss.”
versus
“GLP-1s don’t cause muscle loss.”
The better conversation is:
Weight loss commonly includes some lean tissue loss. How much of that tissue is skeletal muscle? Does strength decline? Does resistance training protect it? Does protein intake change the outcome? And does age or baseline muscle mass completely change the risk?
THAT’S the research question.
And the strongest current evidence gives us one practical signal:
If you’re losing substantial weight, don’t make the scale your only metric.
Pay attention to:
Strength
Resistance training
Protein intake
Physical function
Body composition
and
how rapidly you’re losing weight.
🔴 WHAT WE STILL DON’T KNOW WELL
We still need better research on:
- Women specifically
- Premenopausal vs postmenopausal women
- Resistance-trained women
- High-protein vs low-protein intake
- Long-term strength and functional outcomes
- Retatrutide and other newer multi-agonists
- Whether GLP-1 medications directly affect skeletal muscle biology in humans
That’s where the next several years of research get interesting.
🧪 N=1 EXPERIENCE
When I share my personal experiences with retatrutide, GHK-Cu or other peptides, those observations will stay completely separate from the research.
My experience can tell us:
“This happened to me.”
It cannot tell us:
“This will happen to women.”
That’s an important distinction we’ll keep making inside GOATGETheR.
PEPTIDE EVIDENCE SCORE
Incretin-based weight loss reduces fat mass:
🟢 HIGH CONFIDENCE
Some lean mass is lost during significant weight loss:
🟢 HIGH CONFIDENCE
All lost lean mass = skeletal muscle:
🔴 FALSE OVERSIMPLIFICATION
Strength necessarily declines because lean mass falls:
🟡 NOT ESTABLISHED
GLP-1 medications directly improve muscle quality in humans:
🔴 EARLY / INSUFFICIENT
Resistance training may help preserve lean tissue during weight loss:
🟢 STRONG AND PRACTICALLY IMPORTANT SIGNAL
🔬 THE QUESTION WE’RE WATCHING
Can a woman lose measurable lean mass while actually improving the quality and function of the muscle she keeps?
Right now:
There’s enough evidence to make the question interesting.
Not enough evidence to call the answer settled.
And that’s exactly where GOATGETheR likes to live.
SOURCES
Menstrual research
Kyathanahalli et al., 2025 — systematic review of menstrual-effluent biomarkers. PMID 40616466.
Bernstein et al., 2014 — gastrointestinal symptoms before and during menstruation. PMID 24450290.
Heitkemper et al., 1988 — gastrointestinal symptoms and bowel patterns across the menstrual cycle. PMID 3347518.
GI symptoms and dysmenorrhea three-cycle diary study. PMID 8552802.
Peptide / incretin research
SEMALEAN semaglutide study. PMID 41068996.
2026 incretin vs lifestyle lean-mass RCT meta-analysis. PMID 41877354.
SURMOUNT-1 tirzepatide DXA substudy. PMID 39996356.
2025 review of GLP-1 therapies and skeletal-muscle health.
1
2 comments
📚 RESEARCH MONDAY
powered by
skool.com/goatgether-3744
Evidence-based women’s health, fitness & performance. Research simplified. Build confidence, strength & become a founding member.
Suggested communities
Powered by